Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2016', provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
- The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
- The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Post-Traumatic Stress Disorder (PTSD) Overview 10
Therapeutics Development 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 11
Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 12
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 13
Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 15
Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 20
Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 22
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 23
Addex Therapeutics Ltd 23
Amorsa Therapeutics Inc. 24
Azevan Pharmaceuticals, Inc. 25
Catalyst Pharmaceutical Partners, Inc. 26
Eli Lilly and Company 27
HolsboerMaschmeyer NeuroChemie GmbH 28
Humanetics Corporation 29
Intra-Cellular Therapies, Inc. 30
INVENT Pharmaceuticals, Inc. 31
Marinus Pharmaceuticals, Inc. 32
Neuralstem, Inc. 33
NeuroNascent, Inc. 34
Omeros Corporation 35
Otsuka Holdings Co., Ltd. 36
Polleo Pharma Limited 37
Synchroneuron Inc. 38
Tonix Pharmaceuticals Holding Corp. 39
Turing Pharmaceuticals AG 40
Vanda Pharmaceuticals Inc. 41
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
acamprosate calcium SR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ADX-71743 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AM-3506 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
brexpiprazole - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CPP-115 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug for Post-Traumatic Stress Disorders - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ganaxolone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HL-9001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IC-87201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
iloperidone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
INV-170 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ITI-007 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ketamine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NNI-351 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NSI-189 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Rycal - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
S-107 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SRX-246 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TNX-102 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Vaccine for CNS Disorders - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
vigabatrin - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ZL-006 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates 96
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 124
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 125
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 126
Featured News & Press Releases 126
Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder 126
Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation 126
Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium 127
May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR 128
May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry 128
Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder 128
Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 129
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 129
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 130
Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132

List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2016 11
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Comparative Analysis by Unknown Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2016 23
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc., H1 2016 24
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 25
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 26
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H1 2016 27
Post-Traumatic Stress Disorder (PTSD) - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016 28
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H1 2016 29
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 30
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 31
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 32
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H1 2016 33
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H1 2016 34
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H1 2016 35
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 36
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H1 2016 37
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H1 2016 38
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 39
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Turing Pharmaceuticals AG , H1 2016 40
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 41
Assessment by Monotherapy Products, H1 2016 42
Number of Products by Stage and Target, H1 2016 44
Number of Products by Stage and Mechanism of Action, H1 2016 46
Number of Products by Stage and Route of Administration, H1 2016 48
Number of Products by Stage and Molecule Type, H1 2016 50
Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H1 2016 96
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2016 124
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2016 125